Last reviewed · How we verify
placebo+torasemide
Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary fluid and electrolyte excretion.
Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary fluid and electrolyte excretion. Used for Edema associated with congestive heart failure, Hypertension, Edema associated with renal disease or hepatic cirrhosis.
At a glance
| Generic name | placebo+torasemide |
|---|---|
| Sponsor | Shanghai Chest Hospital |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Torasemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride ions. This leads to increased urine output and reduced fluid volume in the body, lowering blood pressure and reducing edema. The placebo component serves as a control in this formulation.
Approved indications
- Edema associated with congestive heart failure
- Hypertension
- Edema associated with renal disease or hepatic cirrhosis
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
Key clinical trials
- Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (PHASE2)
- A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (PHASE4)
- Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (PHASE2)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- ToRsemide for pOstpartum HYpertension (PHASE2)
- The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement (PHASE4)
- The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |